Changes in other innate cells and cytokines. (A) Changes in expression of CD16 on monocytes during cycle 1. PBMCs obtained from patients before starting therapy (PreC1) as well as from cycle 2 (PreC2) were analyzed for the presence of CD16 on CD14⁺ monocytes using flow cytometry. (Left panel) Data from a representative patient. (Right panel) Summary of pooled data from all patients. (B) Changes in eosinophils. A complete blood count was obtained weekly as part of routine care of the patients. Shown are the changes in eosinophil count as a percentage of white blood cells during therapy. (C) Changes in plasma levels of soluble IL2 receptor during therapy. Plasma obtained from blood collected on patients before starting therapy (PreC1), before starting cycle 2 (PreC2), before starting cycle 3 (PreC3), as well as days 7 and 14 of each cycle was analyzed for the presence of soluble IL2-receptor (sIL-2R) using a multiplex Luminex assay. Shown are the changes in sIL2R expressed as fold change from baseline (before starting cycle 1).